ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a selective small molecule inhibitor targeting the transcription factor NRF2, pivotal in cellular antioxidant and detoxification pathways (APExBIO). It shows nanomolar-to-micromolar IC50 in NSCLC cell models and demonstrates efficacy in attenuating NRF2-mediated gene expression and tumor growth in vivo. ML385 is insoluble in water and ethanol but dissolves at ≥13.33 mg/mL in DMSO, requiring storage at -20°C for stability. Preclinical studies confirm its potential in combination therapy to sensitize cancer cells to chemotherapeutics, with clear mechanistic benchmarks (Zhou et al., 2024). ML385 is a validated tool for dissecting NRF2-dependent signaling and drug resistance across cancer and oxidative stress paradigms.

Biological Rationale

Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor orchestrating the expression of antioxidant and detoxification genes. NRF2 regulates genes critical for glutathione synthesis, NADPH production, and multidrug transporter expression (Zhou et al., 2024). Dysregulation of NRF2 signaling is implicated in therapeutic resistance, particularly in non-small cell lung cancer (NSCLC), where persistent NRF2 activation enhances cell survival and chemoresistance. ML385 was developed to selectively inhibit NRF2 and enable precise manipulation of oxidative stress responses in preclinical models. Targeting NRF2 is increasingly recognized as a strategy to overcome resistance in cancer and metabolic diseases. This approach is distinct from broad-spectrum antioxidants or pro-oxidants, offering pathway-specific modulation and clearer experimental outcomes. For a review of NRF2’s role in resistance and metabolism, see our mechanistic overview, which this article extends with updated efficacy data and practical usage guidance.

Mechanism of Action of ML385

ML385 inhibits the transcriptional activity of NRF2 by binding to its Neh1 DNA-binding domain. This disrupts the interaction between NRF2 and the antioxidant response element (ARE) in downstream gene promoters. ML385 exhibits a half-maximal inhibitory concentration (IC50) of 1.9 μM in A549 NSCLC cells (APExBIO). By blocking NRF2, ML385 downregulates the expression of genes such as NQO1, HO-1, and GCLC, which are responsible for cellular redox homeostasis. Inhibition of NRF2 by ML385 is both dose- and time-dependent, with maximal pathway suppression observed at 24–48 hours post-treatment in vitro. ML385’s selectivity for NRF2 over other transcription factors is supported by transcriptomic and protein-level assays. For more details on practical mechanisms and assay parameters, see our ML385 mechanism guide, which this article updates with recent in vivo benchmarks.

Evidence & Benchmarks

• ML385 suppresses NRF2-driven gene expression in A549 NSCLC cells at an IC50 of 1.9 μM; maximal inhibition achieved within 24–48 h in DMSO-based assays (APExBIO).
• In vivo, ML385 (100 mg/kg/day, intraperitoneal) reduces tumor burden and metastatic spread in NSCLC mouse models, especially when combined with carboplatin (Zhou et al., 2024).
• ML385 antagonizes NRF2-mediated antioxidant responses, reducing glutathione and NADPH pathway gene expression in both cancer and alcoholic liver disease models (Zhou et al., 2024).
• ML385 is insoluble in water and ethanol but soluble to at least 13.33 mg/mL in DMSO at room temperature, with recommended storage at -20°C (APExBIO).
• NRF2 inhibition by ML385 sensitizes cancer cells to chemotherapeutics (e.g., carboplatin) in vitro and in vivo, reducing cell viability and tumor growth (Zhou et al., 2024).

Applications, Limits & Misconceptions

ML385 is primarily deployed for:

• Investigating NRF2 signaling in cancer cell lines and animal models.
• Evaluating the role of NRF2 in oxidative stress and ferroptosis.
• Testing combination therapies targeting drug resistance mechanisms.

For scenario-driven troubleshooting and assay optimization, refer to this Q&A guide, which this article complements by clarifying new in vivo use cases and data interpretation boundaries.

Common Pitfalls or Misconceptions

• ML385 is not a pan-antioxidant: It specifically inhibits NRF2, not general ROS or all redox pathways.
• Solubility constraints: ML385 is unsuitable for aqueous or ethanol-based delivery; use DMSO only.
• Non-cancer models: Efficacy in non-cancerous chronic disease models (e.g., non-alcoholic steatohepatitis) is unproven and should not be assumed.
• Not a direct cytotoxin: ML385’s anticancer effect is due to pathway modulation, not direct cytotoxicity.
• Stability warnings: Solutions are unstable at room temperature over extended periods; avoid long-term storage of working solutions.

Workflow Integration & Parameters

ML385 (SKU B8300) is supplied as a solid for research use, typically reconstituted in DMSO. Recommended stock concentration is ≥13.33 mg/mL (DMSO, room temperature). The product should be stored at -20°C, protected from light. In vitro, dosing ranges from 0.5–10 μM, with optimal inhibition at 1–5 μM in A549 or HepG2 cells over 24–48 h. In vivo, ML385 is administered at 100 mg/kg/day via intraperitoneal injection, as validated in NSCLC mouse models (Zhou et al., 2024). For best practices, avoid repeated freeze-thaw cycles and prepare fresh working solutions. Researchers should validate NRF2 pathway readouts (e.g., NQO1, HO-1 expression) to confirm target engagement. For hands-on troubleshooting and comparative protocols, see our application workflow article, which this article extends with stability and dosing insights.

Conclusion & Outlook

ML385 is a robust, selective NRF2 inhibitor supporting cancer research and oxidative stress pathway dissection. Its well-defined mechanism, reproducible solubility profile, and validated preclinical efficacy make it a cornerstone reagent for studying NRF2’s role in therapeutic resistance and redox biology. APExBIO provides ML385 (SKU B8300) with comprehensive technical support and documentation. As NRF2 targeting becomes integral to cancer and metabolic disease research, ML385 is positioned as a key tool for mechanistic studies and translational development. For product details and ordering, visit the ML385 product page.